AbCellera Biologics Inc [NASDAQ: ABCL] closed the trading session at $3.12.
The stocks have a year to date performance of 6.48 percent and weekly performance of 3.31 percent. The stock has been moved at 5.76 percent over the last six months. The stock has performed 53.69 percent around the most recent 30 days and changed 32.77 percent over the most recent 3-months.
If compared to the average trading volume of 4.65M shares, ABCL reached to a volume of 7374684 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about AbCellera Biologics Inc [ABCL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABCL shares is $8.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABCL stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Benchmark Company have made an estimate for AbCellera Biologics Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on August 20, 2024. The new note on the price target was released on February 22, 2024, representing the official price target for AbCellera Biologics Inc stock. Previously, the target price had yet another raise to $6, while KeyBanc Capital Markets analysts kept a Overweight rating on ABCL stock.
The Average True Range (ATR) for AbCellera Biologics Inc is set at 0.20, with the Price to Sales ratio for ABCL stock in the period of the last 12 months amounting to 40.28. The Price to Book ratio for the last quarter was 0.91, with the Price to Cash per share for the same quarter was set at 2.11.
ABCL stock trade performance evaluation
AbCellera Biologics Inc [ABCL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.31. With this latest performance, ABCL shares gained by 53.69% in over the last four-week period, additionally plugging by 5.76% over the last 6 months – not to mention a drop of -6.31% in the past year of trading.
#####
AbCellera Biologics Inc [ABCL]: An insightful look at the core fundamentals
AbCellera Biologics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.15 and a Current Ratio set at 10.15.
Earnings per share (EPS) analysis for AbCellera Biologics Inc [ABCL] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABCL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbCellera Biologics Inc go to 0.83%.
AbCellera Biologics Inc [ABCL]: Institutional Ownership
The top three institutional holders of ABCL stocks are: BAKER BROS. ADVISORS LP with ownership of 27.53 million shares, which is approximately 9.3556%. BAILLIE GIFFORD & CO, holding 21.91 million shares of the stock with an approximate value of $$64.86 million in ABCL stocks shares; and BAILLIE GIFFORD & CO, currently with $$31.45 million in ABCL stock with ownership which is approximately 3.611%.
